1542P - Exploratory analyses of candidate predictive and prognostic tissue biomarkers (BMs) in the open-label randomised phase III TANIA trial of bevacizumab (BEV) in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
| Autor: | Zielinski, C., Gligorov, J., Marschner, N., Puglisi, F., Vrdoljak, E., Castan, J. Cortes, de Ducla, S., Deurloo, R., Easton, V., von Minckwitz, G. |
|---|---|
| Zdroj: | In Annals of Oncology 1 October 2016 27 Supplement 6:vi533-vi533 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|